Objectives This study aimed to systematically review the literature on the efficacy and
immunogenicity of single-dose HPV vaccination compared to no vaccination or multi-dose …

Background Primary analyses of a study in young women aged 16–26 years showed
efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52 …

Cervical cancer, the most common cancer affecting women in developing countries, is
caused by persistent infection with" high-risk" genotypes of human papillomaviruses (HPV) …

BACKGROUND: We present a long-term safety, immunogenicity, and effectiveness study of
a quadrivalent human papillomavirus (HPV4) vaccine. METHODS: Sexually naive boys and …

Cervical cancer results from cervical infection by human papillomaviruses (HPV), especially
HPV16. Previous studies have shown that intramuscular vaccination of women with an …

The recognition of a strong etiological relationship between infection with high-risk human
papillomavirusses and cervical cancer has prompted research to develop and evaluate …

Human papillomavirus (HPV) is one of the most common sexually transmitted diseases
(STDs) and is frequently presented clinically as anogenital warts in both males and females …

Objectives To assess the safety and immunogenicity of the investigational 9-valent
(6/11/16/18/31/33/45/52/58) HPV (9vHPV) vaccine in prior recipients of a 3-dose regimen of …

Human papillomavirus (HPV) vaccines are among the most effective vaccines available, the
first to prevent infection by a mucosatropic sexually transmitted infectious agent and to do so …

Human papillomavirus (HPV) is the most common sexually transmitted infection in the
United States, and persistent HPV infection is strongly associated with risk of cervical cancer …